RSV is the leading viral agent causing severe respiratory tract disease worldwide in older adults. It is also a common cause of pneumonia and bronchiolitis in small children. There is a medical need to improve patient quality of life by preventing lower respiratory tract disease (LRTD).

This study will evaluate the clinical efficacy of a new RSV mRNA vaccine in people 60+ years of age.

Main Exclusions*:
– Allergic reactions (e.g. anaphylaxis) to mRNA vaccines.
– Known systemic hypersensitivity to vaccines or vaccine components.
– Diagnosed RSV infection in previous 12 months.
– Previous history of myocarditis, pericarditis, and / or myo-pericarditis.
– Received any mRNA vaccine in the last 60 days.
– Received any vaccine in the last 4 weeks or plan to receive any vaccine in the 4 weeks following study vaccine administration.
– Previously been vaccinated against RSV.

* This list is not exhaustive.

TO REGISTER, PLEASE FOLLOW THE LINK AT THE BOTTOM OF THIS PAGE.